Biodesix

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Closeup,Of,Wall,St.,Street,Sign,And,Large,New,York

Earnings

Equities

Government

Market Summary

News

Futures

Commodities

Economics

Pre-Market Outlook

Markets

Analyst Ratings

BDSX

CRWD

GDOT

SPGC

SPHR

TNYA

U.S. stock futures declined on Tuesday following the worst trading day of 2025 on Monday. Futures fell in premarket trading except Nasdaq 100.

US Futures Tumble As Traders Await Trump&#39;s Congress Address: &#39;Volatility Is Certainly Being Fed By Trump 2.0 Moves,&#39; Says Expert

movers image

Movers

Trading Ideas

AVGR

AZTR

BURU

CETX

ELAB

OCFT

RENB

SAVE

SMMT

SNAL

SOBR

TIGR

UAVS

Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

APDN

VIGL

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock&#39;s current market price does not adequately reflect its higher earnings, it suggests potential for growth.

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Biodesix Inc

Press Releases

Biodesix to Present at Two Investor Conferences in September

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Biodesix to Participate in Three Investor Conferences in November

Biodesix Announces Third Quarter 2024 Results and Highlights

Health Care

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Talkspace

Vivos Therapeutics

Scotiabank

Craig-Hallum

TD Cowen

Lake Street

Canaccord Genuity

Comments

Biodesix

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga